Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
University of Oklahoma Health Sciences Center · Duke University Health System · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
530
total citations
- FWCI
- 31.01
- Percentile
- 100%
- References
- 35
Citations per year
Authors
20- KNKathleen N. MooreCorresponding
University of Oklahoma Health Sciences Center
- AAAngeles Alvarez Secord
Duke University Health System
- MAMelissa A. Geller
University of Minnesota
- DSDavid S. Miller
The University of Texas Southwestern Medical Center, Southwestern Medical Center, Southwestern Medical Center
- NCNoelle Cloven
Texas Oncology
Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Ovarian cancer
- BRCA mutation
- Oncology
- Progressive disease
- Chemotherapy
- Progression-free survival
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.